Eli Lilly and Company (LLY)
| Market Cap | 679.76B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 897.99M |
| EPS (ttm) | 11.71 |
| PE Ratio | 64.64 |
| Forward PE | 32.56 |
| Dividend | $6.00 (0.79%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 1,417,276 |
| Open | 755.19 |
| Previous Close | 754.35 |
| Day's Range | 752.28 - 764.47 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 1,020.35 (+34.79%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,020.35, which is an increase of 34.79% from the latest price.
News
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries
The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the m...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Wegovy, Zepbound makers' stocks rally as a weight-loss-drug competitor drops out
Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift in early Monday trading, after a potential competitor decided to cancel development of its GLP-1 drug.
Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near
Eli Lilly has shown strong financial performance, driven by key drugs like Mounjaro and Zepbound, but shares remain expensive relative to peers, justifying a 'hold' rating. Revenue, profits, and cash ...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthcare Stocks Aren't a Shelter From the Tariff Storm
It's increasingly clear that broad bets on healthcare don't make sense as a refuge from the market chaos.
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
NVDA & INTC Behind AMD Downgrade, WFC & LLY Upgrades
Keybanc downgraded AMD Inc. (AMD) to Sector Weight from Overweight, but it didn't shake the stock's rally alongside the market. Diane King Hall talks about why Nvidia (NVDA) and Intel (INTC) are behin...
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted Spencer Perlman, director of Healthcare Research at Veda Partners, an investment advisory and consulting firm with extensive expertise in government policy analysis. During the conversa...
Trump drops Biden's proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. But the ...
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.